Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. The company was founded in 2012 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone415-818-1001
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees152
OptionableOptionable
Audentes Therapeutics (NASDAQ:BOLD) Frequently Asked Questions
What is Audentes Therapeutics' stock symbol?
Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."
How were Audentes Therapeutics' earnings last quarter?
Audentes Therapeutics Inc (NASDAQ:BOLD) posted its earnings results on Tuesday, November, 6th. The biotechnology company reported ($0.97) EPS for the quarter, missing the Zacks' consensus estimate of ($0.88) by $0.09. During the same quarter in the prior year, the firm posted ($0.88) earnings per share. View Audentes Therapeutics' Earnings History.
When is Audentes Therapeutics' next earnings date?
What price target have analysts set for BOLD?
11 Wall Street analysts have issued 1-year target prices for Audentes Therapeutics' shares. Their forecasts range from $20.00 to $49.00. On average, they anticipate Audentes Therapeutics' stock price to reach $32.2122 in the next twelve months. This suggests a possible upside of 32.4% from the stock's current price. View Analyst Price Targets for Audentes Therapeutics.
What is the consensus analysts' recommendation for Audentes Therapeutics?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Audentes Therapeutics in the last year. There are currently 2 sell ratings, 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Audentes Therapeutics.
What are Wall Street analysts saying about Audentes Therapeutics stock?
Here are some recent quotes from research analysts about Audentes Therapeutics stock:
- 1. HC Wainwright analysts commented, "Our Buy rating and $33 price target on shares of Audentes are currently leveraged on AT132. We have removed AT342 from our estimates pending clinical clarity anticipated during the company’s 1Q19 call estimated in May 2019. Given the robustness of the clinical data thus far, and the rarity of the condition, we are increasing our AT132 launch price to $1.7M vs. our prior estimate of $1M, which drives AT132 NPV to $33/share, vs. our prior $17/share." (1/11/2019)
- 2. According to Zacks Investment Research, "Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company's product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California. " (1/8/2019)
- 3. Mizuho analysts commented, "We do not see earnings as the best indicator of value for an early-stage biotech. Importantly, progress continues to be highly encouraging on the AT-132 program. Audentes is expected to meet with the FDA and EMA in 4Q18 to discuss development plans and a potential registrational pathway for AT132. An update is expected in 1Q19, which could be an important catalyst. Two other pipeline products; in Criggler-Najjar and Pompe disease need further work (more below). Finally, a new program targeting a large neuromuscular disease remains to be disclosed, which could add upside to the shares as well." (11/7/2018)
Has Audentes Therapeutics been receiving favorable news coverage?
Press coverage about BOLD stock has trended somewhat negative on Friday, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Audentes Therapeutics earned a daily sentiment score of -1.1 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are some of Audentes Therapeutics' key competitors?
Some companies that are related to Audentes Therapeutics include Ablynx (ABLYF), Allogene Therapeutics (ALLO), argenx (ARGX), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA), Spark Therapeutics (ONCE), Regenxbio (RGNX), Editas Medicine (EDIT) and Autolus Therapeutics (AUTL).
Who are Audentes Therapeutics' key executives?
Audentes Therapeutics' management team includes the folowing people:
- Mr. Matthew R. Patterson, Co-Founder, Chairman & CEO (Age 46)
- Ms. Natalie C. Holles, Pres & COO (Age 45)
- Mr. Thomas P. Soloway, Sr. VP & CFO (Age 51)
- Dr. John T. Gray, Sr. VP & Chief Scientific Officer (Age 55)
- Mr. Andrew H. Chang, Director of Investor Relations
When did Audentes Therapeutics IPO?
(BOLD) raised $75 million in an IPO on Wednesday, July 20th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Audentes Therapeutics' major shareholders?
Audentes Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.02%). Company insiders that own Audentes Therapeutics stock include 5Am Partners Iii, Llc, David Nagler, John T Gray, Louis G Lange, Mary Newman, Matthew R Patterson, Orbimed Advisors Llc and Suyash Prasad. View Institutional Ownership Trends for Audentes Therapeutics.
Which institutional investors are buying Audentes Therapeutics stock?
How do I buy shares of Audentes Therapeutics?
Shares of BOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Audentes Therapeutics' stock price today?
One share of BOLD stock can currently be purchased for approximately $24.33.
How big of a company is Audentes Therapeutics?
Audentes Therapeutics has a market capitalization of $1.05 billion. The biotechnology company earns $-90,230,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Audentes Therapeutics employs 152 workers across the globe.
What is Audentes Therapeutics' official website?
How can I contact Audentes Therapeutics?
Audentes Therapeutics' mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company can be reached via phone at 415-818-1001 or via email at [email protected]
MarketBeat Community Rating for Audentes Therapeutics (NASDAQ BOLD)
MarketBeat's community ratings are surveys of what our community members think about Audentes Therapeutics and other stocks. Vote "Outperform" if you believe BOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.
